title: Correlation between a short-term intravenous octreotide suppression test and response to antrectomy in patients with type-1 gastric neuroendocrine tumours.
abstract: BACKGROUND
  Type-1 gastric neuroendocrine tumours (NETs) arise in some patients with chronic hypergastrinaemia secondary to autoimmune atrophic gastritis. Patients with small tumours are usually managed conservatively, because their prognosis is very good. However, larger tumours may require surgical intervention. Many type-1 gastric NETs regress following antrectomy because this removes the source of hypergastrinaemia. However, some tumours do not regress following antrectomy and additional surgery may be required. An octreotide suppression test has been previously suggested as a means to assess whether type-1 gastric NETs are likely to regress following antrectomy.
  
  
  OBJECTIVE
  To prospectively examine the role of a short-term intravenous octreotide suppression test in predicting type-1 gastric NET regression in five patients who subsequently underwent antrectomy.
  
  
  METHODS
  Serum gastrin concentrations and gastric corpus and tumour histidine decarboxylase mRNA abundances were assessed in patients with type-1 gastric NETs before and 72 h after the administration of 25 µg/h intravenous octreotide. Gastric tumour response was assessed endoscopically following subsequent antrectomy.
  
  
  RESULTS
  All patients showed significant decreases in serum gastrin concentrations as well as corpus and tumour biopsy histidine decarboxylase mRNA abundance following octreotide infusion. All patients also showed resolution of hypergastrinaemia following subsequent antrectomy. However, tumour regression was only observed in four of the five patients. One patient had a persistent tumour 3 years after antrectomy and required additional surgical resection.
  
  
  CONCLUSIONS
  A positive octreotide suppression test result does not always predict response to antrectomy in patients with type-1 gastric NETs. Assessment of gastric mucosal responses to a gastrin/CCK-2 receptor antagonist may therefore also be helpful.
authors.affiliation: Department of Gastroenterology, Institute of Translational Medicine, University of Liverpool, Liverpool L69 3GE, UK.
authors.forename: Senthil V
authors.initials: SV
authors.lastname: Murugesan
authors.forename: Islay A
authors.initials: IA
authors.lastname: Steele
authors.forename: Rod
authors.initials: R
authors.lastname: Dimaline
authors.forename: Graeme J
authors.initials: GJ
authors.lastname: Poston
authors.forename: Milind
authors.initials: M
authors.lastname: Shrotri
authors.forename: Fiona
authors.initials: F
authors.lastname: Campbell
authors.forename: Andrea
authors.initials: A
authors.lastname: Varro
authors.forename: D Mark
authors.initials: DM
authors.lastname: Pritchard
mesh_terms: D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D005260:Female; D005743:Gastrectomy / Q000379:methods; D005755:Gastrins / Q000097:blood; D005773:Gastroscopy / Q000379:methods; D006640:Histidine Decarboxylase / Q000096:biosynthesis / Q000235:genetics; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D018358:Neuroendocrine Tumors / Q000175:diagnosis* / Q000601:surgery; D015282:Octreotide / Q000008:administration & dosage; D018579:Patient Selection; D011379:Prognosis; D011446:Prospective Studies; D011706:Pyloric Antrum / Q000601:surgery*; D012333:RNA, Messenger / Q000235:genetics; D013274:Stomach Neoplasms / Q000175:diagnosis* / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D005755:Gastrins; D012333:RNA, Messenger; D006640:Histidine Decarboxylase; D015282:Octreotide